Clinical

Dataset Information

0

A Single-Center, Phase II Study of mFOLFOXIRI Combined with Camrelizumab and Bevacizumab in the Neoadjuvant Treatment of Non MSI-H/dMMR Colorectal Cancer

ABSTRACT: Interventions: Experimental group:mFOLFOXIRI + Camrelizumab + Bevacizumab Primary outcome(s): Complete remission rate Study Design: Single arm

DISEASE(S): Colorectal Cancer

PROVIDER: 2761907 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Json Xml

Similar Datasets

Unknown Efficacy and Safety of Neoadjuvant Monoimmunotherapy With PD-1 Inhibitor for dMMR/MSI⁃H Locally Advanced Colorectal Cancer: A Single-Center Real-World Study.
| S-EPMC9359076 | biostudies-literature
Unknown Efficacy and Safety of Camrelizumab in Combination with Docetaxel + S-1 Sequenced by Camrelizumab + S-1 for Stage III (PD-1+/MSI-H/EBV+/dMMR) Gastric Cancer: Study Protocol for a Single-Center, Prospective, Open-Label, Single-Arm Trial.
| S-EPMC9274117 | biostudies-literature
Unknown Neoadjuvant immunotherapy for nonmetastatic dMMR/MSI colon cancer: a real-world retrospective AGEO study.
| S-EPMC12337657 | biostudies-literature
Unknown Neoadjuvant Immunotherapy for MSI-H/dMMR Locally Advanced Colorectal Cancer: New Strategies and Unveiled Opportunities.
| S-EPMC8968082 | biostudies-literature
Unknown Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience.
| S-EPMC9632313 | biostudies-literature
Unknown Locally advanced rectal cancer with dMMR/MSI-H may be excused from surgery after neoadjuvant anti-PD-1 monotherapy: a multiple-center, cohort study.
| S-EPMC10333582 | biostudies-literature
Clinical Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer
| 2375994 | ecrin-mdr-crc
Unknown Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
| S-EPMC8649008 | biostudies-literature
Unknown Long-term survivals of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy in dMMR/MSI-H colorectal and gastric cancers.
| S-EPMC11226604 | biostudies-literature
Unknown Prevalence and Associations of Beta2-Microglobulin Mutations in MSI-H/dMMR Cancers.
| S-EPMC10020813 | biostudies-literature